Ian Quigley says Leash Bio's current task focuses on finding molecules that bind better to a target and does not yet address other drug-like properties.

“We're not doing those right now. We're just doing, can we find molecules that bind better to the thing that we're interested in? And so what we do is we take mode-- we take an agent, like a language model, and then we say, "Here's a catalog that you could look at.”